Assessing the Influence of Propylthiouracil and Phenytoin on the Metabolomes of the Thyroid, Liver, and Plasma in Rats.
hypothyroidism
metabolomics
phenytoin
propylthiouracil
thyroid hormones
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
06
03
2023
revised:
26
06
2023
accepted:
06
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The thyroid hormones (THs) regulate various physiological mechanisms in mammals, such as cellular metabolism, cell structure, and membrane transport. The therapeutic drugs propylthiouracil (PTU) and phenytoin are known to induce hypothyroidism and decrease blood thyroid hormone levels. To analyze the impact of these two drugs on systemic metabolism, we focused on metabolic changes after treatment. Therefore, in a rat model, the metabolome of thyroid and liver tissue as well as from the blood plasma, after 2-week and 4-week administration of the drugs and after a following 2-week recovery phase, was investigated using targeted LC-MS/MS and GC-MS. Both drugs were tested at a low dose and a high dose. We observed decreases in THs plasma levels, and higher doses of the drugs were associated with a high decrease in TH levels. PTU administration had a more pronounced effect on TH levels than phenytoin. Both drugs had little or no influence on the metabolomes at low doses. Only PTU exhibited apparent metabolome alterations at high doses, especially concerning lipids. In plasma, acylcarnitines and triglycerides were detected at decreased levels than in the controls after 2- and 4-week exposure to the drug, while sphingomyelins and phosphatidylcholines were observed at increased levels. Interestingly, in the thyroid tissue, triglycerides were observed at increased concentrations in the 2-week exposure group to PTU, which was not observed in the 4-week exposure group and in the 4-week exposure group followed by the 2-week recovery group, suggesting an adaptation by the thyroid tissue. In the liver, no metabolites were found to have significantly changed. After the recovery phase, the thyroid, liver, and plasma metabolomic profiles showed little or no differences from the controls. In conclusion, although there were significant changes observed in several plasma metabolites in PTU/Phenytoin exposure groups, this study found that only PTU exposure led to adaptation-dependent changes in thyroid metabolites but did not affect hepatic metabolites.
Identifiants
pubmed: 37512556
pii: metabo13070847
doi: 10.3390/metabo13070847
pmc: PMC10383188
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Chemical Industry Council
ID : C5 - XomeTox
Références
Eur J Endocrinol. 2018 Oct 12;179(5):R261-R274
pubmed: 30320502
J Mol Cell Cardiol. 2007 Jan;42(1):186-95
pubmed: 17069849
Lancet. 2017 Sep 23;390(10101):1550-1562
pubmed: 28336049
Xenobiotica. 2014 May;44(5):391-403
pubmed: 24175917
Am J Physiol. 1978 Aug;235(2):E231-6
pubmed: 686169
Cell Physiol Biochem. 2012;29(5-6):713-24
pubmed: 22613972
Nucleic Acids Res. 2016 Jan 4;44(D1):D463-70
pubmed: 26467476
Horm Metab Res. 1998 Mar;30(3):137-40
pubmed: 9566855
Physiol Rev. 2014 Apr;94(2):355-82
pubmed: 24692351
Epilepsia. 1995 Nov;36(11):1118-25
pubmed: 7588456
J Lipid Res. 1992 Feb;33(2):241-9
pubmed: 1569376
Toxicol Lett. 2007 Jul 30;172(1-2):21-8
pubmed: 17614222
Rapid Commun Mass Spectrom. 2011 Oct 30;25(20):3123-30
pubmed: 21953968
Exp Brain Res. 2021 Aug;239(8):2435-2444
pubmed: 34106297
Toxicol Sci. 2002 Sep;69(1):79-91
pubmed: 12215662
J Anal Toxicol. 2002 Jan-Feb;26(1):17-22
pubmed: 11888012
Acta Histochem. 2011 Jan;113(1):1-5
pubmed: 19775732
Front Neurosci. 2020 Dec 04;14:586939
pubmed: 33343282
Lancet. 2012 Mar 24;379(9821):1142-54
pubmed: 22273398
Regul Toxicol Pharmacol. 2003 Dec;38(3):368-77
pubmed: 14623486
Nat Rev Cardiol. 2017 Jan;14(1):39-55
pubmed: 27811932
Bioanalysis. 2012 Sep;4(18):2291-301
pubmed: 23046269
J Lipid Res. 1981 Feb;22(2):287-96
pubmed: 6787158
Nat Rev Endocrinol. 2016 Feb;12(2):111-21
pubmed: 26668118
Medicine (Baltimore). 2018 Oct;97(43):e12938
pubmed: 30412107
Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E642-7
pubmed: 17047159
Toxicol Lett. 2014 Mar 3;225(2):240-51
pubmed: 24370789
Fed Proc. 1980 Jan;39(1):31-6
pubmed: 7351242
Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1071-9
pubmed: 23946049
Eur J Endocrinol. 1997 Mar;136(3):324-9
pubmed: 9100559
Toxicol Lett. 2012 Nov 30;215(2):143-9
pubmed: 23103988
Arch Toxicol. 2005 Jul;79(7):390-405
pubmed: 15692820
Metabolomics. 2014;10(1):152-164
pubmed: 24955082
Toxicol Lett. 2014 Nov 4;230(3):467-78
pubmed: 25086301
J Pharm Biomed Anal. 2013 Jan;72:109-14
pubmed: 23146233
Lancet. 2016 Aug 27;388(10047):906-918
pubmed: 27038492
Sci Rep. 2017 Sep 11;7(1):11207
pubmed: 28894120
J Biol Chem. 2017 Sep 15;292(37):15434-15444
pubmed: 28743746
J Endocrinol Invest. 2021 Jun;44(6):1309-1319
pubmed: 33025552
PLoS One. 2013;8(2):e55599
pubmed: 23409005
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159059
pubmed: 34619367